GLP-1 / GIP Weight Loss · Michigan
Tirzepatide Weight Loss in Michigan
Medically supervised dual GLP-1/GIP therapy with a double board-certified physician and PA-C. Individualized dosing protocols delivering maximum results — not just a prescription.
20.9%
Average body weight lost in SURMOUNT-1 trial
72
Weeks of studied therapy duration
1×
Weekly injection — simple adherence
96%
Of patients lost ≥ 5% body weight
What Is Tirzepatide
A dual-action medication that resets how your body manages weight
Tirzepatide is a dual GIP and GLP-1 receptor agonist — the first medication of its kind approved for chronic weight management. By activating two distinct hormone pathways simultaneously, tirzepatide produces significantly greater weight loss than GLP-1-only therapies like semaglutide.
Brand names include Zepbound® (FDA-approved for weight loss) and Mounjaro® (FDA-approved for Type 2 diabetes).
Why the dual mechanism matters: GIP receptors are found in fat tissue, the brain, and the pancreas. Adding GIP agonism on top of GLP-1 enhances insulin sensitivity, reduces fat storage, and may produce greater satiety signaling — which is why SURMOUNT trial results significantly outpaced earlier GLP-1-only data.
Mechanism of Action
How tirzepatide works
1
Dual Receptor Activation
Tirzepatide binds to both GIP and GLP-1 receptors in the pancreas, gut, fat tissue, and brain — engaging two distinct hormone pathways simultaneously for enhanced metabolic effect.
2
Enhanced Appetite Suppression
Signals in the hypothalamus reduce food cravings and caloric drive through both GIP and GLP-1 pathways — patients consistently report greater appetite reduction compared to single-agonist therapy.
3
Improved Fat Metabolism
GIP receptor activation in adipose tissue directly reduces fat storage and enhances insulin sensitivity — a mechanism absent in GLP-1-only medications like semaglutide.
4
Gradual Dose Escalation
MWLI physicians titrate dose slowly — starting at 2.5 mg and increasing every 4 weeks — to minimize side effects while maximizing fat loss over time.
Clinical Evidence
What the research shows
Tirzepatide’s SURMOUNT trial program produced the most significant weight loss outcomes ever recorded for a pharmaceutical intervention.
20.9%
Mean Weight Loss
Average body weight reduction at highest dose over 72 weeks in SURMOUNT-1.
SURMOUNT-1, NEJM 2022
96%
Lost ≥ 5% Body Weight
Nearly all patients on tirzepatide achieved clinically meaningful weight reduction vs. 28% on placebo.
SURMOUNT-1, NEJM 2022
57%
Lost ≥ 20% Body Weight
More than half of patients achieved weight loss previously seen only with bariatric surgery.
SURMOUNT-1, NEJM 2022
Individual results vary. Clinical trial results reflect outcomes in controlled research settings with lifestyle support. MWLI programs include nutritional guidance and behavioral coaching to support optimal outcomes.
Eligibility
Who qualifies for tirzepatide at MWLI?
Your MWLI physician will conduct a full medical evaluation. General criteria follow FDA labeling and clinical guidelines.
You may qualify if you have:
One or more criteria typically satisfies medical eligibility
- BMI of 30 or higher (obesity)
- BMI of 27 or higher with at least one weight-related condition
- Prior difficulty maintaining weight loss through diet and exercise alone
- Inadequate response or plateau on semaglutide or another GLP-1
- No contraindicated medical history (reviewed at consultation)
- Commitment to regular monitoring and follow-up visits
Tirzepatide is not appropriate if you have:
Absolute contraindications — alternatives are available for many patients
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to tirzepatide or excipients
- Current pregnancy or active breastfeeding
- Certain pancreatic conditions (evaluated at consultation)
Not sure if you qualify?
An MWLI physician will review your full history and recommend the right treatment — whether that’s tirzepatide, semaglutide, or another approach.
The MWLI Process
From consultation to results
01
Request a Consultation
Meet with an MWLI physician to review your health history, goals, and medication options. Consultations are billed to insurance.
02
Medical Evaluation
Lab work, vitals, and a comprehensive metabolic assessment. We verify insurance and benefits at this stage.
03
Personalized Protocol
Your physician prescribes a titration schedule — beginning at 2.5 mg and escalating every 4 weeks — alongside nutrition and behavior support.
04
Ongoing Monitoring
Regular follow-up visits track progress, manage any side effects, and adjust your protocol to sustain results long-term.
Common Questions
Tirzepatide FAQs
How much weight can I lose with tirzepatide?
Many patients lose 15–22% of their body weight with tirzepatide. In the SURMOUNT-1 trial, patients on the highest dose averaged 20.9% body weight loss over 72 weeks. Results vary based on your starting weight, dosage, lifestyle, and medical history. At Michigan Weight Loss Institute, we create personalized treatment plans to support safe and sustainable weight loss.
Is tirzepatide better than semaglutide for weight loss?
Head-to-head trial data (SURMOUNT-5) shows tirzepatide produces significantly greater average weight loss than semaglutide. Tirzepatide’s dual GIP/GLP-1 mechanism engages two distinct hormone pathways, which may explain the superior results. Individual responses vary — your MWLI physician will review your history and recommend the best option for you.
Does insurance cover tirzepatide for weight loss in Michigan?
Coverage for tirzepatide varies by plan. Zepbound® (the weight loss indication) is covered by some Michigan insurance plans, though prior authorization is often required. Mounjaro® (the diabetes indication) has broader coverage for patients with Type 2 diabetes. Our team helps verify your benefits and navigate the prior authorization process when needed.
What are the side effects of tirzepatide?
Common side effects include nausea, diarrhea, constipation, vomiting, decreased appetite, and indigestion. Most side effects are mild to moderate and improve over time. MWLI physicians use a gradual titration protocol to minimize discomfort while maximizing results.
How long do I need to take tirzepatide?
Tirzepatide supports long-term weight management and metabolic health. The length of treatment depends on your goals, medical history, and overall progress. Your MWLI provider will create a plan tailored to your needs.
Can I switch to tirzepatide if semaglutide stopped working?
Yes. Patients who have plateaued on semaglutide are a common candidate group for tirzepatide at MWLI. Because tirzepatide activates an additional receptor (GIP), it can produce renewed and substantial weight loss even in patients who no longer respond to GLP-1-only therapy.
Is MWLI’s tirzepatide brand-name or compounded?
Michigan Weight Loss Institute may offer FDA-approved brand-name tirzepatide (Zepbound® or Mounjaro®) based on your insurance coverage, medical history, and treatment goals. Your treatment recommendation will be individualized at your consultation.
Michigan Locations
Visit us in Sterling Heights or Bingham Farms
Sterling Heights
Sterling Heights
41400 Dequindre Rd #105
Sterling Heights, MI 48314
586-287-7330
Sterling Heights, MI 48314
586-287-7330
In-person & telehealth
Directions & Info →
Bingham Farms
Bingham Farms
32000 Telegraph Rd
Bingham Farms, MI 48025
248-573-3110
Bingham Farms, MI 48025
248-573-3110
In-person & telehealth
Directions & Info →
Telehealth
Telehealth
Limited telehealth availability — contact us to discuss options.
In-person & telehealth
Contact Us →
Ready to start? Request a consultation.
Dr. Rita Kathawa will review your history, answer your questions, and recommend the right GLP-1 protocol for you. Consultations are billed to insurance.
